AbCellera Q2 net loss widens on higher expenses
AbCellera Q2 net loss widens on higher expenses
Overview
US biotechnology firm's Q2 revenue declined and missed analyst expectations
Net loss widened to $55.4 mln from $34.7 mln a year earlier
Company signed new collaborations with Jazz and Vertex, adding over $100 mln upfront cash
Outlook
Company expects top-line data from ABCL635 Phase 2 trial in August 2026
Top-line data from ABCL575 Phase 1 study expected in Q4 2026
AbCellera to receive over $100 mln in upfront cash from recent collaborations
Result Drivers
R&D SPENDING - Co said higher research and development expenses contributed to wider net loss
NEW COLLABORATIONS - Co signed deals with Jazz and Vertex, adding over $100 mln in upfront cash
Company press release: ID:nBw2ZPClLa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Miss | $4.1 mln | $7.78 mln (7 Analysts) |
Q2 Net Loss |
| $55.4 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for AbCellera Biologics Inc. is $11.00, about 80.6% above its August 4 closing price of $6.09
Reuters Recommended Reads
Aug 3 - Ireland's Jazz Pharma Q2 revenue beats estimates on Zepzelca higher sales
Aug 3 - Vertex Q2 revenue beats estimates on strong demand for cystic fibrosis therapies, lifts outlook
Aug 5 - Recursion Pharmaceuticals Q2 revenue misses estimates, cuts 2026 expense outlook
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on AbCellera Biologics
See all newsAbCellera Biologics Inc. reports results for the quarter ended September 30 - Earnings Summary
Canada's AbCellera Q3 revenue beats analyst estimates
Factbox: Pharma sector doubles down on AI to slash costs, timelines
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce